The MKNK2 antibody is a research tool designed to detect and analyze the mitogen-activated protein kinase (MAPK)-interacting serine/threonine kinase 2 (MKNK2), a protein involved in cellular signaling pathways. MKNK2. also known as MNK2. is part of the MAPK cascade and regulates mRNA translation by phosphorylating eukaryotic initiation factor 4E (eIF4E), influencing protein synthesis under stress or growth stimuli. It exists in two isoforms (MNK2a and MNK2b) due to alternative splicing, with distinct roles in cell proliferation, survival, and stress responses.
MKNK2 antibodies are widely used in Western blotting, immunohistochemistry, and immunofluorescence to study protein expression, localization, and activity in various tissues and cell lines. Researchers employ these antibodies to explore MKNK2’s interaction with upstream regulators (e.g., ERK, p38 MAPK) and downstream targets, particularly in cancer biology and inflammatory diseases. Notably, MKNK2’s dual role as a tumor promoter or suppressor, depending on cellular context, has spurred interest in its therapeutic targeting.
Studies using MKNK2 antibodies have linked its dysregulation to cancers, neurodegenerative disorders, and immune dysfunctions. Validated antibodies help clarify its contribution to drug resistance, metastasis, and survival pathways. As MKNK2 inhibitors enter clinical trials, these antibodies remain critical for mechanistic insights and biomarker development, underscoring their importance in translational research.